Drug Trial Radar · NCT07842445
Phase 1a/1b Clinical Trials to Evaluate the Safety and Preliminary Efficacy of GNTbm-38.
Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Dec 1, 2026
Primary completion
Feb 28, 2029
Study completion Jun 30, 2029
Sponsor
- Lead sponsor
- Great Novel Therapeutics Biotech & Medicals CorporationIndustry
- Sponsor type
- Industry
- First posted
- Sep 25, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of GNTbm-38 in adult patients with advanced solid tumors and R/R PTCL.
Conditions
- Solid Tumor (Phase I)
- Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Interventions
GNTbm-38Drug
Phase 1a is the dose escalation phase to firstly determine the MTD of patients with solid tumor. Once MTD for solid tumor patients has been established, the next lower dose of this MTD will serve as an initial dose to determine the MTD for patients with R/R PTCL. Phase 1b is the dose expansion phase to evaluate the safety, tolerability, and efficacy of GNTbm-38 in R/R PTCL patients.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1a: The MTD and DLT of GNTbm-38Time frame: At the end of Cycle 1 (each cycle is 28 days)
- Phase Ia: To define the safety and tolerabilityTime frame: At the end of Cycle 1 (each cycle is 28 days)
- Phase Ib: To evaluate the efficacy of GNTbm-38 in patients with R/R PTCL.Time frame: At the end of Cycle 1 (each cycle is 28 days)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.